Immunohistochemical study of DNA topoisomerase I, p53, and Ki-67 in uterine carcinosarcomas

Human Pathology

Volumn 38, Issue 8, 2007, Pages 1226-1231

  Lee, Sun Joo ^a   Kim, Hye Sun ^b   Kim, Hy Sook ^b   Chun, Yi Kyung ^b   Hong, Sung Ran ^b   Lee, Je Ho ^c  

^a Konkuk University Hospital   (South Korea)

^b Cheil General Hospital   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Carcinosarcoma; DNA topoisomerase I; Immunohistochemistry; p53 protein; Uterus

Indexed keywords

DNA TOPOISOMERASE; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; PARAFFIN; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA REPLICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEDICAL RECORD; PROTEIN EXPRESSION; TUMOR CELL; UTERUS CARCINOMA; UTERUS SARCOMA;

AGED; AGED, 80 AND OVER; CARCINOSARCOMA; DNA TOPOISOMERASES, TYPE I; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS;

EID: 34447325617     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.01.012     Document Type: Article

References (28)

1. Gadducci A., Sartori E., Landoni F., et al. The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases. Eur J Gynaecol Oncol 23 (2002) 295-299
2. Menczer J., Levy T., Piura B., et al. A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol 97 (2005) 166-170
3. Silverberg S.G., Major F.J., Blessing J.A., et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 9 (1990) 1-19
4. McCluggage W.G. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 12 (2002) 687-690
5. Sutton G.P., Blessing J.A., Rosenshein N., et al. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). Am J Obstet Gynecol 161 (1989) 309-312
6. Curtin J.P., Blessing J.A., Soper J.T., et al. Paclitaxel in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 83 (2001) 268-270
7. Thigpen J.T., Blessing J.A., Beecham J., et al. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 9 (1991) 1962-1966
8. Miller D.S., Blessing J.A., Schilder J., et al. Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 98 (2005) 217-221
9. Stewart L., Redinbo M.R., Qiu X., et al. A model for the mechanism of human topoisomerase I. Science 279 (1998) 1534-1541
10. Covey J.M., Jaxel C., Kohn K.W., et al. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res 49 (1989) 5016-5022
11. Nitiss J.L., and Wang J.C. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol Pharmacol 50 (1996) 1095-1102
12. Bronstein I.B., Vorobyev S., Timofeev A., et al. Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies. Oncol Res 8 (1996) 17-25
13. Hann C., Evans D.L., Fertala J., et al. Increased camptothecin toxicity induced in mammalian cells expressing Saccharomyces cerevisiae DNA topoisomerase I. J Biol Chem 273 (1998) 8425-8433
14. Madden K.R., and Champoux J.J. Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin. Cancer Res 52 (1992) 525-532
15. Bjornsti M.A., Benedetti P., Viglianti G.A., et al. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res 49 (1989) 6318-6323
16. Lowe S.W., Ruley H.E., Jacks T., et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74 (1993) 957-967
17. Caserini C., Pratesi G., Tortoreto M., et al. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies. Clin Cancer Res 3 (1997) 955-961
18. Ariyoshi K., Kawauchi S., Kaku T., et al. Prognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases. Histopathology 37 (2000) 427-436
19. Lynch B.J., Komaromy-Hiller G., Bronstein I.B., et al. Expression of DNA topoisomerase I, DNA topoisomerase II-alpha, and p53 in metastatic malignant melanoma. Hum Pathol 29 (1998) 1240-1245
20. Tomicic M.T., Christmann M., and Kaina B. Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival. Cancer Res 65 (2005) 8920-8926
21. Hafian H., Venteo L., Sukhanova A., et al. Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas. Hum Pathol 35 (2004) 745-751
22. Brambilla E., Negoescu A., Gazzeri S., et al. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 149 (1996) 1941-1952
23. Jalava P., Kuopio T., Juntti-Patinen L., et al. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki6 immunoreactivity and standardized mitotic index. Histopathology 48 (2006) 674-682
24. Pitot H.C., Wender D.B., O'Connell M.J., et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 15 (1997) 2910-2919
25. Creemers G.J., Bolis G., Gore M., et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 14 (1996) 3056-3061
26. Iwasa Y., Haga H., Konishi I., et al. Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients. Cancer 82 (1998) 512-519
27. Barwick K.W., and LiVolsi V.A. Malignant mixed müllerian tumors of the uterus: a clinicopathologic assessment of 34 cases. Am J Surg Pathol 3 (1979) 125-135
28. George E., Manivel J.C., Dehner L.P., et al. Malignant mixed müllerian tumors: an immunohistochemical study of 47 cases, with histogenetic considerations and clinical correlation. Hum Pathol 22 (1991) 215-223